Duodenal levodopa infusion in Parkinson's disease--long-term experience

Acta Neurologica Scandinavica
D NilssonS M Aquilonius

Abstract

Motor fluctuations in parkinsonian patients can be reduced by intraduodenal infusion of levodopa. Between 1991 and 1998 continuous daytime administration of levodopa through a transabdominal port has been used in 28 very advanced patients over a total period of 1045 months. A stable suspension of levodopa and carbidopa (Duodopa) has been developed. Patients were characterized by early onset, long history of disease and levodopa therapy. The reason for infusion was in all cases related to on-off fluctuations. All patients experienced a general improvement after the introduction of continuous treatment. There have been no severe complications. Six patients have taken the decision to curtail their treatment. The mean daily levodopa consumption has been slightly reduced on infusion as compared to oral therapy. Nine of the first group of patients participating in the new therapy have been regularly evaluated by means of rating scales and movement analyses. Short-term results have already been published and a follow-up showing continued positive effect after 4-7 years of continuous duodenal infusion is presented.

References

Jan 1, 1989·Acta Neurologica Scandinavica. Supplementum·G StegM Thorselius
Mar 1, 1989·Acta Neurologica Scandinavica·B JohnelsG Steg
Apr 1, 1989·Neurology·J R Keane
Jul 1, 1988·Annals of Neurology·J I SageR C Duvoisin
Oct 1, 1987·Annals of Neurology·M M MouradianT N Chase
Apr 16, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·N SyedJ I Sage
Aug 26, 1998·Neurology·T N ChaseP J Blanchet

❮ Previous
Next ❯

Citations

Nov 19, 2008·Journal of Neurology·Francesca Del Sorbo, Alberto Albanese
Mar 5, 2013·Journal of Neural Transmission·K Ray ChaudhuriKapil D Sethi
Apr 9, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Stewart A Factor
Jul 25, 2003·International Journal of Pharmaceutics·Susanne BredenbergChrister Nyström
Oct 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yoland SmithMahlon R DeLong
May 3, 2007·Journal of Palliative Medicine·Lauren B ElmanLeo McCluskey
Jun 5, 2003·Clinical Neuropharmacology·Dag NyholmSten-Magnus Aquilonius
Dec 17, 2004·Clinical Neuropharmacology·Dag Nyholm, Sten-Magnus Aquilonius
Apr 3, 2008·Clinical Neuropharmacology·Dag NyholmSten-Magnus Aquilonius
Mar 7, 2008·Neuro-degenerative Diseases·A AntoniniG Pezzoli
May 25, 2011·Drug Design, Development and Therapy·Patrick Hickey, Mark Stacy
Dec 11, 2013·CNS Drugs·Marina Senek, Dag Nyholm
Jan 1, 2014·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Barbara Anne PickutDiederik Zegers de Beyl
May 1, 2009·Journal of Movement Disorders·Angelo Antonini
Nov 9, 2011·The International Journal of Neuroscience·Robert A Hauser
Jun 12, 2014·Expert Review of Neurotherapeutics·Karoline WenzelCarlo Colosimo
Mar 1, 2011·Current Medical Research and Opinion·H H Fernandez, P Odin
Nov 22, 2005·Expert Opinion on Drug Delivery·Tom H JohnstonJonathan M Brotchie
Feb 24, 2016·Current Neurology and Neuroscience Reports·Yasaman Kianirad, Tanya Simuni
Jan 31, 2014·Journal of Neurology·María T Cáceres-RedondoPablo Mir
Mar 23, 2007·Expert Opinion on Pharmacotherapy·Johan Samanta, Robert A Hauser
Apr 15, 2016·Neurodegenerative Disease Management·Diego Santos GarcíaNatividad Mariscal Pérez
Jun 19, 2015·Acta neurologica Belgica·F BellanteD Zegers de Beyl
Dec 2, 2008·Trends in Pharmacological Sciences·Anthony H V Schapira
Mar 1, 2009·Therapeutic Advances in Neurological Disorders·O K Sujith, Carol Lane
Mar 10, 2017·Upsala Journal of Medical Sciences·Sten-Magnus Aquilonius, Dag Nyholm
Oct 21, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Anne Marthe MeppelinkKlaus Leonhard Leenders
Sep 8, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·John G Nutt

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.